GT Biopharma宣布首例患者接受B7-H3靶向NK细胞衔接剂GTB-5550一期临床试验给药

美股速递
May 14

GT Biopharma Inc. 近日宣布,其针对实体瘤的B7-H3靶向自然杀伤(NK)细胞衔接剂GTB-5550,已在第一期临床试验中为首位患者完成给药。

这项试验标志着该公司在开发新型免疫肿瘤疗法方面迈出了关键一步。GTB-5550旨在通过特异性靶向在多种实体瘤中过度表达的B7-H3蛋白,从而激活并引导患者自身的NK细胞攻击肿瘤细胞。

该一期临床试验的主要目标将评估GTB-5550在晚期实体瘤患者中的安全性、耐受性、药代动力学特性以及初步的抗肿瘤活性。公司表示,后续将根据试验进展适时公布更多数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10